Literature DB >> 20605784

The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.

Linda M McAllister-Lucas1, Xiaohong Jin, Shufang Gu, Katy Siu, Scott McDonnell, Jürgen Ruland, Phillip C Delekta, Matthew Van Beek, Peter C Lucas.   

Abstract

The CARMA1, Bcl10, and MALT1 proteins together constitute a signaling complex (CBM signalosome) that mediates antigen-dependent activation of NF-kappaB in lymphocytes, thereby representing a cornerstone of the adaptive immune response. Although CARMA1 is restricted to cells of the immune system, the analogous CARMA3 protein has a much wider expression pattern. Emerging evidence suggests that CARMA3 can substitute for CARMA1 in non-immune cells to assemble a CARMA3-Bcl10-MALT1 signalosome and mediate G protein-coupled receptor activation of NF-kappaB. Here we show that one G protein-coupled receptor, the type 1 receptor for angiotensin II, utilizes this mechanism for activation of NF-kappaB in endothelial and vascular smooth muscle cells, thereby inducing pro-inflammatory signals within the vasculature, a key factor in atherogenesis. Further, we demonstrate that Bcl10-deficient mice are protected from developing angiotensin-dependent atherosclerosis and aortic aneurysms. By uncovering a novel vascular role for the CBM signalosome, these findings illustrate that CBM-dependent signaling has functions outside the realm of adaptive immunity and impacts pathobiology more broadly than previously known.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605784      PMCID: PMC2923974          DOI: 10.1074/jbc.C110.109421

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Authors:  Georg Lenz; R Eric Davis; Vu N Ngo; Lloyd Lam; Thaddeus C George; George W Wright; Sandeep S Dave; Hong Zhao; Weihong Xu; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Wing C Chan; Louis M Staudt
Journal:  Science       Date:  2008-03-06       Impact factor: 47.728

2.  The proteolytic activity of the paracaspase MALT1 is key in T cell activation.

Authors:  Fabien Rebeaud; Stephan Hailfinger; Anita Posevitz-Fejfar; Myriam Tapernoux; Roger Moser; Daniel Rueda; Olivier Gaide; Montserrat Guzzardi; Emanuela M Iancu; Nathalie Rufer; Nicolas Fasel; Margot Thome
Journal:  Nat Immunol       Date:  2008-02-10       Impact factor: 25.606

Review 3.  Biomarkers of AAA progression. Part 1: extracellular matrix degeneration.

Authors:  Femke A M V I Hellenthal; Willem A Buurman; Will K W H Wodzig; Geert Willem H Schurink
Journal:  Nat Rev Cardiol       Date:  2009-05-26       Impact factor: 32.419

Review 4.  CD154 and its receptors in inflammatory vascular pathologies.

Authors:  Ghada S Hassan; Yahye Merhi; Walid M Mourad
Journal:  Trends Immunol       Date:  2009-03-11       Impact factor: 16.687

Review 5.  The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue.

Authors:  Bonnie K Surmi; Alyssa H Hasty
Journal:  Vascul Pharmacol       Date:  2009-12-21       Impact factor: 5.773

6.  Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice.

Authors:  A Daugherty; M W Manning; L A Cassis
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 7.  CARMA1-mediated NF-kappaB and JNK activation in lymphocytes.

Authors:  Marzenna Blonska; Xin Lin
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

Review 8.  Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction.

Authors:  René R S Packard; Peter Libby
Journal:  Clin Chem       Date:  2008-01       Impact factor: 8.327

Review 9.  Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis.

Authors:  Daiju Fukuda; Masataka Sata
Journal:  Pharmacol Ther       Date:  2008-03-10       Impact factor: 12.310

10.  Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO.

Authors:  Honglin Zhou; Ingrid Wertz; Karen O'Rourke; Mark Ultsch; Somasekar Seshagiri; Michael Eby; Wei Xiao; Vishva M Dixit
Journal:  Nature       Date:  2003-12-24       Impact factor: 49.962

View more
  37 in total

Review 1.  NF-κB signaling pathways regulated by CARMA family of scaffold proteins.

Authors:  Marzenna Blonska; Xin Lin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

2.  MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

Authors:  Peter C Lucas; Linda M McAllister-Lucas; J Randall McAuley; Kelly M Bailey; Prasanna Ekambaram; Linda R Klei; Heejae Kang; Dong Hu; Tanner J Freeman; Vincent J Concel; Nathaniel E Hubel; Jia-Ying Lloyd Lee; Hanna B Klei; Jing Cheng; Preethiya Sekar; Rachel E Bridwell; Lidija Covic
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

3.  The adaptor CRADD/RAIDD controls activation of endothelial cells by proinflammatory stimuli.

Authors:  Huan Qiao; Yan Liu; Ruth A Veach; Lukasz Wylezinski; Jacek Hawiger
Journal:  J Biol Chem       Date:  2014-06-23       Impact factor: 5.157

4.  CARMA3 Is Critical for the Initiation of Allergic Airway Inflammation.

Authors:  Benjamin Causton; Ravisankar A Ramadas; Josalyn L Cho; Khristianna Jones; Ana Pardo-Saganta; Jayaraj Rajagopal; Ramnik J Xavier; Benjamin D Medoff
Journal:  J Immunol       Date:  2015-06-03       Impact factor: 5.422

Review 5.  From MALT lymphoma to the CBM signalosome: three decades of discovery.

Authors:  Shaun Rosebeck; Aasia O Rehman; Peter C Lucas; Linda M McAllister-Lucas
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

Review 6.  Regulation of NF-κB by the CARD proteins.

Authors:  Changying Jiang; Xin Lin
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

7.  Specific effects of BCL10 Serine mutations on phosphorylations in canonical and noncanonical pathways of NF-κB activation following carrageenan.

Authors:  Sumit Bhattacharyya; Alip Borthakur; Arivarasu N Anbazhagan; Shivani Katyal; Pradeep K Dudeja; Joanne K Tobacman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-06-23       Impact factor: 4.052

Review 8.  MALT1 protease: a new therapeutic target in B lymphoma and beyond?

Authors:  Linda M McAllister-Lucas; Mathijs Baens; Peter C Lucas
Journal:  Clin Cancer Res       Date:  2011-08-25       Impact factor: 12.531

9.  CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells.

Authors:  Tingting Zhao; Zhifeng Miao; Zhenning Wang; Yingying Xu; Jianhua Wu; Xingyu Liu; Yi You; Jiguang Li
Journal:  Tumour Biol       Date:  2013-05-25

10.  Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment.

Authors:  K Nho; J J Corneveaux; S Kim; H Lin; S L Risacher; L Shen; S Swaminathan; V K Ramanan; Y Liu; T Foroud; M H Inlow; A L Siniard; R A Reiman; P S Aisen; R C Petersen; R C Green; C R Jack; M W Weiner; C T Baldwin; K Lunetta; L A Farrer; S J Furney; S Lovestone; A Simmons; P Mecocci; B Vellas; M Tsolaki; I Kloszewska; H Soininen; B C McDonald; M R Farlow; B Ghetti; M J Huentelman; A J Saykin
Journal:  Mol Psychiatry       Date:  2013-04-23       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.